A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of PF-07899895 Administered as Immediate and Modified Release Formulations in Healthy Adult Participants
Latest Information Update: 30 May 2025
At a glance
- Drugs PF 07899895 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 23 May 2025 Planned End Date changed from 12 Dec 2025 to 19 Feb 2026.
- 23 May 2025 Planned primary completion date changed from 12 Dec 2025 to 19 Feb 2026.
- 13 Apr 2025 Planned End Date changed from 19 Jun 2025 to 12 Dec 2025.